100 related articles for article (PubMed ID: 16784849)
1. Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
Lin HR; Abraham DJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4178-83. PubMed ID: 16784849
[TBL] [Abstract][Full Text] [Related]
2. Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.
Lin HR; Safo MK; Abraham DJ
Bioorg Med Chem Lett; 2007 May; 17(9):2581-9. PubMed ID: 17337183
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
[TBL] [Abstract][Full Text] [Related]
4. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.
Han KC; Kim JH; Kim KH; Kim EE; Seo JH; Yang EG
Anal Biochem; 2010 Mar; 398(2):185-90. PubMed ID: 19913492
[TBL] [Abstract][Full Text] [Related]
5. Recognition of LXXLL by ligand binding domain of the Farnesoid X receptor in molecular dynamics simulation.
Zhang T; Dong XC; Chen MB
J Chem Inf Model; 2006; 46(6):2623-30. PubMed ID: 17125202
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
Kainuma M; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
[TBL] [Abstract][Full Text] [Related]
7. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
[TBL] [Abstract][Full Text] [Related]
8. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
Feng S; Yang M; Zhang Z; Wang Z; Hong D; Richter H; Benson GM; Bleicher K; Grether U; Martin RE; Plancher JM; Kuhn B; Rudolph MG; Chen L
Bioorg Med Chem Lett; 2009 May; 19(9):2595-8. PubMed ID: 19328688
[TBL] [Abstract][Full Text] [Related]
9. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.
Huang H; Yu Y; Gao Z; Zhang Y; Li C; Xu X; Jin H; Yan W; Ma R; Zhu J; Shen X; Jiang H; Chen L; Li J
J Med Chem; 2012 Aug; 55(16):7037-53. PubMed ID: 22862148
[TBL] [Abstract][Full Text] [Related]
11. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
12. Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.
Meyer U; Costantino G; Macchiarulo A; Pellicciari R
J Med Chem; 2005 Nov; 48(22):6948-55. PubMed ID: 16250653
[TBL] [Abstract][Full Text] [Related]
13. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
14. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
[TBL] [Abstract][Full Text] [Related]
15. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
Honorio KM; Garratt RC; Andricopulo AD
Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X-activated receptor antagonists from a marine sponge Spongia sp.
Nam SJ; Ko H; Shin M; Ham J; Chin J; Kim Y; Kim H; Shin K; Choi H; Kang H
Bioorg Med Chem Lett; 2006 Oct; 16(20):5398-402. PubMed ID: 16905319
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of potent antitumor and antiviral benzofuran derivatives.
Galal SA; Abd El-All AS; Abdallah MM; El-Diwani HI
Bioorg Med Chem Lett; 2009 May; 19(9):2420-8. PubMed ID: 19345581
[TBL] [Abstract][Full Text] [Related]
18. DNA binding and transactivation properties of the Schistosoma mansoni constitutive androstane receptor homologue.
Hu R; Niles EG; LoVerde PT
Mol Biochem Parasitol; 2006 Dec; 150(2):174-85. PubMed ID: 16962182
[TBL] [Abstract][Full Text] [Related]
19. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
Katona BW; Cummins CL; Ferguson AD; Li T; Schmidt DR; Mangelsdorf DJ; Covey DF
J Med Chem; 2007 Nov; 50(24):6048-58. PubMed ID: 17963371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
